Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?

Emilia Sawicka; Anna Mirończuk; Marek Z. Wojtukiewicz; Ewa Sierko

doi:10.5114/wo.2016.60066

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2016
vol. 20

Send email

Copy url:

abstract:

Review paper

Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?

Emilia Sawicka

,

Anna Mirończuk

,

Marek Z. Wojtukiewicz

,

Ewa Sierko

Contemp Oncol (Pozn) 2016; 20 (2): 102-108

DOI: https://doi.org/10.5114/wo.2016.60066

Online publish date: 2016/06/14

View full text Get citation

PlumX metrics:

Operable pancreatic cancer is characterized by a high risk of recurrence. Efforts are made to incorporate new therapies. Throughout the world there is a lack of uniform recommendations concerning the adjuvant treatment of pancreatic cancer patients, due to confusing evidence-based data. The patients recruited to clinical trials differ from the population of patients treated in everyday practice. These differences have an influence on tolerance of treatment, toxicity and results of therapy. The decision on administration of adjuvant treatment is made individually and differs from center to center. A review of the literature concerning both results and tolerance of postoperative chemoradiotherapy of pancreatic cancer patients is presented.

keywords:

Chemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?

Emilia Sawicka , Anna Mirończuk , Marek Z. Wojtukiewicz , Ewa Sierko

pancreatic cancer, adjuvant chemoradiotherapy, radiotherapy, gemcitabine, 5-fluorouracil, toxicity

Emilia Sawicka

,

Anna Mirończuk

,

Marek Z. Wojtukiewicz

,

Ewa Sierko